Trials / Completed
CompletedNCT01415414
Observational Study of Ultravist in Patients Requiring CECT
The Image Quality and Radiation Dose of CECT With Ultravist® in Patients With Abdominal Pelvic Disease - INDEX
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 11,660 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
It is a prospective, non-interventional, multi-center study. The primary objective of this study is to evaluate the image quality of Ultravist in patients requiring contrast-enhanced CT considering the routine use in patient population's, region's indication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iopromide (Ultravist, BAY86-4877) | CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2012-07-01
- Completion
- 2013-11-01
- First posted
- 2011-08-12
- Last updated
- 2015-01-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01415414. Inclusion in this directory is not an endorsement.